prikaz prve stranice dokumenta Cryoballoon ablation vs. antiarrhythmic drugs: first-line therapy for patients with paroxysmal atrial fibrillation
  Download
PDF 693.62 KB
Scientific paper - Original scientific paper
Cryoballoon ablation vs. antiarrhythmic drugs: first-line therapy for patients with paroxysmal atrial fibrillation
EP Europace, 23 (2021), 7; 1033-1041. https://doi.org/10.1093/europace/euab029
(Cryo-FIRST Investigators) Kuniss, Malte; Pavlović, Nikola; Velagić, Vedran; Hermida, Jean Sylvain; Healey, Stewart; Arena, Giuseppe; Badenco, Nicolas; Meyer, Christian; Chen, Jian; Iacopino, Saverio; Anselme, Frédéric; Packer, Douglas L.; Pitschner, Heinz-Friedrich; Asmundis, Carlo de; Willems, Stephan; Di Piazza, Fabio; Becker, Daniel; Chierchia, Gian-Battista More authors...

Cite this document

Kuniss, M., Pavlović, N., Velagić, V., Hermida, J. S., Healey, S., Arena, G. ... Chierchia, G. B. (2021). Cryoballoon ablation vs. antiarrhythmic drugs: first-line therapy for patients with paroxysmal atrial fibrillation. EP Europace, 23. (7), 1033-1041. doi: 10.1093/europace/euab029

Kuniss, Malte, et al. "Cryoballoon ablation vs. antiarrhythmic drugs: first-line therapy for patients with paroxysmal atrial fibrillation." EP Europace, vol. 23, no. 7, 2021, pp. 1033-1041. https://doi.org/10.1093/europace/euab029

Kuniss, Malte, Nikola Pavlović, Vedran Velagić, Jean Sylvain Hermida, Stewart Healey, Giuseppe Arena, Nicolas Badenco, et al. "Cryoballoon ablation vs. antiarrhythmic drugs: first-line therapy for patients with paroxysmal atrial fibrillation." EP Europace 23, no. 7 (2021): 1033-1041. https://doi.org/10.1093/europace/euab029

Kuniss, M., et al. (2021) 'Cryoballoon ablation vs. antiarrhythmic drugs: first-line therapy for patients with paroxysmal atrial fibrillation', EP Europace, 23(7), pp. 1033-1041. doi: 10.1093/europace/euab029

Kuniss M, Pavlović N, Velagić V, Hermida JS, Healey S, Arena G, and sur.. Cryoballoon ablation vs. antiarrhythmic drugs: first-line therapy for patients with paroxysmal atrial fibrillation. EP Europace [Internet]. 2021 July 18 [cited 2024 October 05];23(7):1033-1041. doi: 10.1093/europace/euab029

M. Kuniss, et al., "Cryoballoon ablation vs. antiarrhythmic drugs: first-line therapy for patients with paroxysmal atrial fibrillation", EP Europace, vol. 23, no. 7, pp. 1033-1041, July 2021. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:223841. [Accessed: 05 October 2024]

Please login to the repository to save this object to your list.
Metadata
Title (english)Cryoballoon ablation vs. antiarrhythmic drugs: first-line therapy for patients with paroxysmal atrial fibrillation
AuthorMalte Kuniss
AuthorNikola Pavlović
AuthorVedran Velagić
AuthorJean Sylvain Hermida
AuthorStewart Healey
AuthorGiuseppe Arena
AuthorNicolas Badenco
AuthorChristian Meyer
AuthorJian Chen
AuthorSaverio Iacopino
AuthorFrédéric Anselme
AuthorDouglas L. Packer
AuthorHeinz-Friedrich Pitschner
AuthorCarlo de Asmundis
AuthorStephan Willems
AuthorFabio Di Piazza
AuthorDaniel Becker
AuthorGian-Battista Chierchia
CollaborationCryo-FIRST Investigators
Author's institutionUniversity of Zagreb
School of Medicine
(Department of Internal Medicine)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Internal Medicine
Abstract (english)
Aims: Treatment guidelines for patients with atrial fibrillation (AF) suggest that patients should be managed with an antiarrhythmic drug (AAD) before undergoing catheter ablation (CA). This study evaluated whether pulmonary vein isolation employing cryoballoon CA is superior to AAD therapy for the prevention of atrial arrhythmia (AA) recurrence in rhythm control naive patients with paroxysmal AF (PAF). ----- Methods and results: A total of 218 treatment naive patients with symptomatic PAF were randomized (1 : 1) to cryoballoon CA (Arctic Front Advance, Medtronic) or AAD (Class I or III) and followed for 12 months. The primary endpoint was ≥1 episode of recurrent AA (AF, atrial flutter, or atrial tachycardia) >30 s after a prespecified 90-day blanking period. Secondary endpoints included the rate of serious adverse events (SAEs) and recurrence of symptomatic palpitations (evaluated via patient diaries). Freedom from AA was achieved in 82.2% of subjects in the cryoballoon arm and 67.6% of subjects in the AAD arm (HR = 0.48, P = 0.01). There were no group differences in the time-to-first (HR = 0.76, P = 0.28) or overall incidence [incidence rate ratio (IRR)=0.79, P = 0.28] of SAEs. The incidence rate of symptomatic palpitations was lower in the cryoballoon (7.61 days/year) compared with the AAD arm (18.96 days/year; IRR = 0.40, P < 0.001). ----- Conclusions: Cryoballoon CA was superior to AAD therapy, significantly reducing AA recurrence in treatment naive patients with PAF. Additionally, cryoballoon CA was associated with lower symptom recurrence and a similar rate of SAEs compared with AAD therapy.
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review
Publication versionPublished version
Journal titleEP Europace
Numberingvol. 23, no. 7, pp. 1033-1041
p-ISSN1099-5129
e-ISSN1532-2092
DOIhttps://doi.org/10.1093/europace/euab029
URN:NBNurn:nbn:hr:105:223841
Publication2021-07-18
Document URLhttps://academic.oup.com/europace/article/23/7/1033/6174429
Type of resourceText
Access conditionsOpen access
Terms of useLicence Attribution-NonCommercial 4.0 International (CC BY-NC 4.0) icon
Created on2021-10-12 08:56:42